- The European stock market is currently dominated by a slight weakening of indices, with the STOXX 600 trading slightly below the line, and the mood being set by concerns about international trade and the technology/AI sector.
- At today’s session, European indices are showing mixed movements, with Croda (+2.0% after good 2025 annual results with higher sales and margins), Endesa (+4.1%), Edenred (+5.2%) and Convatec (+9.2%) leading the gains. On the other hand, Novo Nordisk (-3.5%), Unite (-7.1%) and Fresenius Medical Care (-9.8%) are leading the declines amid general trade uncertainty and sector challenges in pharmaceuticals and real estate.
- Investors are reacting to the new tariffs introduced by President Donald Trump, which are increasing uncertainty about future US-EU trade relations and the impact on economic growth.
- There is a concern that the accumulation of tariffs (including 15% under Section 212) may raise effective rates above previously agreed maximums.
- The banking sector in Europe is performing weaker, following declines on Wall Street amid concerns that the development of AI could disrupt traditional business models in finance in the medium term.
Heatmap of volatility currently visible on the European market. Source: xStation- MTU Aero Engines published fourth quarter results above consensus (adjusted revenue of EUR 2.44 billion versus expected EUR 2.39 billion), benefiting from high demand for GTF engine maintenance services. The company forecasts revenues and profits for 2026 to be broadly in line with market expectations, pointing to the continuing high volume of engine overhauls related to technical problems with Pratt & Whitney engines in the A320neo. Whitney engines in the A320neo. MTU emphasises that the effect of the P&W repair programme (higher service visits) is supporting demand, but at the same time is weighing on margins due to the higher share of programme costs, in which MTU has an approximately 18% share. The management board believes that the company “has exploited most of the market opportunities in 2025” and remains well positioned for further growth in 2026, which the market interprets as confirmation of a stable earnings path in the aviation sector despite GTF problems.
- In the pharmaceutical/obesity drugs segment, Novo Nordisk and China’s United Laboratories report data from the mid-stage trial of the “triple G” candidate UBT251, showing an average weight loss of 19.7% after 24 weeks compared to 2% in the placebo group with a baseline weight of approximately 92.2 kg. UBT251 is a triple agonist (GLP-1, GIP and glucagon), which theoretically may be even more effective than classic GLP-1 drugs such as Wegovy or Zepbound, and Novo describes the results from China as very promising. For comparison, the company’s earlier weight loss drug, CagriSema, achieved a 25.5% weight reduction in 84 weeks in a head-to-head study, while Eli Lilly’s competing tirzepatide (Mounjaro/Zepbound) achieved 23% after the same period.
- The company’s shares are losing another 3.5% today.
Source: xStation
- The New Zealand dollar is currently performing best on the forex market, while the Japanese yen is performing worst.
The material on this page does not constitute financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other specific needs. All information provided, including opinions, market research, mathematical results and technical analyzes published on the Website or transmitted To you by other means, it is provided for information purposes only and should in no way be construed as an offer or solicitation for a transaction in any financial instrument, nor should the information provided be construed as advice of a legal or financial nature on which any investment decisions you make should be based exclusively To your level of understanding, investment objectives, financial situation, or other specific needs, any decision to act on the information published on the Website or sent to you by other means is entirely at your own risk if you In doubt or unsure about your understanding of a particular product, instrument, service or transaction, you should seek professional or legal advice before trading. Investing in CFDs carries a high level of risk, as they are leveraged products and have small movements Often the market can result in much larger movements in the value of your investment, and this can work against you or in your favor. Please ensure you fully understand the risks involved, taking into account investments objectives and level of experience, before trading and, if necessary, seek independent advice.
